Bill & Melinda Gates first bought a stake in Pfizer back in 2002 with the stated intention of "expand[ing] access to the pharmaceutical company's all-in-one injectable contraceptive, Sayana Press, to give to women in the Global South.

⚠️ INSIDER TRADING ALERT ⚠️

The Gates Foundation first bought a position in BioNTech in September 2019, just before the COVID-19 pandemic hit. It invested $55 million in the biotech, with the potential for total funding to reach $100 million.
https://www.fool.com/investing/2020/09/24/4-coronavirus-vaccine-stocks-the-bill-melinda-gate/

Technical writeup on the exacerbation of airborne pathogen due to masking.
Megan Kristen Mansell

1_5186291331974037996.pdf

I shared this back at the end of December beginning of January but in case anybody has missed it this Catherine Austin Fitts for Planet Lockdown
https://earthheroestv.com/programs/catherine-austin-fitts-full-interview-planet-lockdownmp4-508b4a

Moderna gene modification side effects. ⁣If you don't want to watch the whole video, or have time to watch the whole video, you can skip to the summary which starts at 29:23 
https://brandnewtube.com/watch/moderna-vaccine-wreaks-havoc-on-lytton-bc-dr-charles-hoffe-blows-the-whistle_nviTJuO5XfEBpy8.html

The textbook definition of vaccine Antibody-Dependent Enhancement or ADE is when the vaccine creates non neutralizing antibodies (non NAb). Although gene modification studies claim they create NAbs, there is a question as to whether they do or not. With natural immunity T-cells will do the work of recognising the 29 proteins of SARSCoV2. With gene modification they are supposed to only recognise the spike protein. The risk of a gene modified person being exposed to ADE is higher than with the natural disease as they have fewer memory T cells ready for the entire 29 proteins of SARSCoV2:

https://www.nature.com/articles/s41598-021-81629-2

"In this study, we show that the early appearance of SARS-CoV-2 NAbs at high levels was not associated with milder disease nor with early clearance of the virus. Early appearance of NAbs has previously shown to occur in those with severe disease compared to those with mild illness17. It was recently shown that a high frequency of extrafollicular B cells development is seen in COVID-19, which correlated with disease severity. These extrafollicular B cells were responsible for development of development of SARS-CoV-2 specific neutralizing antibodies, very early during illness, which was shown to associate with severe disease18. In addition to production of NAbs by extrafollicular B cells, the early appearance of NAbs in patients with more severe disease could be due to the boosting of NAbs specific to previous coronaviruses. Therefore, early appearance of such cross-reactive antibody responses could have a potential to cause severe illness by antibody dependent enhancement19. Higher initial viral loads were associated with progression to more severe disease in SARS20,21. Therefore, higher viral loads could drive a more robust NAb response. However, infants who were symptomatic had higher nasopharyngeal viral loads, but less severe illness compared to older children with more severe illness22, suggesting that higher viral loads were not necessarily associated with more severe illness.

It was seen that by the end of 4 weeks, 11% of individuals did not have adequate quantities of NAbs. Since the onset of the outbreak, due to the lack of specific treatment options, convalescent plasma of recovered patients with COVID-19 has been used to treat patients with moderate or severe COVID-19 illness23,24. The FDA, USA has issued an emergency use authorization for the use of convalescent plasma as it was believed that it may be effective23. Although randomized clinical trials have not been conducted to determine the efficacy of this treatment, as use of convalescent plasma depends on the presence of high levels of NAbs, it is recommended to test the presence of high titres, before selection of potential donors25,26.

The relationship between the appearance of NAb with duration of virus shedding has not been previously studied. Surprisingly, those who had prolonged shedding had higher levels of NAbs than those who cleared the virus, and the NAbs appeared in such prolonged shedders earlier than in those who cleared the virus earlier. In Sri Lanka, until recently, patients with COVID-19 were only discharged from hospital if they had 2 negative PCRs, 24 h apart. Therefore, despite these prolonged shedders developing antibodies earlier than those who cleared the virus, and at higher titres, they still continued to shed the virus. Although the majority of such prolonged shedders had lower viral titres (Ct values > 30), some individuals still had higher viral loads even after 30 days of illness. As many other countries do not keep patients in hospital until they become PCR negative, the relationship between early appearance of NAbs and yet persistence has not been documented previously and questions the role of NAb alone in viral clearance."

There are two possible explanations for this:
-As SARSCoV2 replicates in bacteria, it can replicate in water sources in India and other places which do not monitor the drinking water, which may include parts of Brasil too.
-Antibody-Dependent Enhancement has started in India
https://cmeindia.in/how-the-second-wave-of-covid-is-unfolding-itself/

Makers of COVID-19 vaccines are now destroying long-term safety studies by unblinding their trials and giving the control groups the active vaccine, claiming it is “unethical” to withhold an effective vaccine - https://articles.mercola.com/sites/articles/archive/2021/04/20/coronavirus-vaccine-safety-studies.aspx

⬆️ India

SARSCoV2 replicates in your bacteria regardless of whether you test PCR positive. Antibiotics not rushed gene modifications are required. https://www.researchgate.net/publication/350192978_SARS-CoV-2_Detection_in_Fecal_Sample_from_a_Patient_with_Typical_Findings_of_COVID-19_Pneumonia_on_CT_but_Negative_to_Multiple_SARS-CoV-2_RT-PCR_Tests_on_Oropharyngeal_and_Nasopharyngeal_Swab_Samples_

India: 180 deaths after Covid-19 jabs till March 31, 75% within 3 days https://timesofindia.indiatimes.com/india/180-deaths-after-jabs-till-mar-31-75-within-3-days/articleshow/81978526.cms

We need to go on the counter-attack. Full exposure of enemy combatants. We can still do this on Telegram.

Enemy combatants, Gates allies.
Look at ECOHEALTH ALLIANCE
https://www.freitag.de/autoren/gunnar-jeschke/netzwerken-fuer-fortgeschrittene ⬇️⬇️⬇️

"The shortest connection from Wuhan to investment banking is the New York-based EcoHealth Alliance ( Figure 1 ). Its President Peter Daszak and WIV scientists published a total of 18 peer-reviewed articles between 2005 and 2020, mostly on the subject of corona viruses in bats and their relationship to human SARS diseases. One of those publicationsfrom 2016 can in a certain sense be seen as evidence for the sentence quoted above in the German Wikipedia. It actually describes how an infectious variant was generated from the non-infectious virus WIV1 by genetic engineering and the success of this method was tested in human cell lines. It is highly likely that these viruses would have been dangerous if released. However, it is also certain that the viruses described in this publication are not SARS-Cov2. There was a moratorium on such “gain of function” (GOF) research in the USA from 2014-2017. The fact that Peter Daszak was able to circumvent this without losing his US research funding is justified by the fact that the research began before the moratorium began. At the time, however, US researchers received letters urging them to stop work on the GOF immediately.
The most prominent connection to investment banking comes from Sheila Patel, who works as honorary director in the EcoHealth Alliance and has been a partner at Goldman Sachs since 2006, where she was head of Goldman Sachs Asset Management until the end of 2020. That is an outstanding leadership position. She continues to be an advisory director at Goldman Sachs. She was a director at the EcoHealth Alliance back in 2008 when it was still called the Wildlife Trust. Further connections to the investment capital market result from the very active honorary director Nancye Green, who advises investors and founders, Ellen Shedlarz, who held high positions in human resources at Morgan Stanley and Ziff Brothers Investment, Margery Fischbein, Head of Healthcare Investment Banking at Seaport Global and Robert Hoguet, who comes from investment banking, but in his old age has actually dedicated himself to the preservation of the cranes .
The EcoHealth Alliance
With the change of name from Wildlife Trust to EcoHealth Alliance in 2010, the organization took account of a change in its character that had already taken place. You can still make a few animal friends in the board of directors and even take on new ones. With the exception of the remaining Pamela Thye and Robert Hoguet, however, they care less about wildlife than about domestic animals in cities ( Amy Attas , Frederick Baum , Kimberly Spina). It becomes more interesting when it comes to health. The partners includeJohnson & Johnson, a pharmaceutical company that has since developed a corona vaccine. She immediately sent her Vice President for Global Public Health to the Board of Directors. Ben Plumley, also on the Board of Directors, was previously Vice President for Global Access and Partnerships at Johnson & Johnson. Other Board links to the pharmaceutical industry include Nancy Griffin, who runs Alliance Management at Vertex Pharmaceuticals and was previously Head of Global Alliance Management at Novartis, and Lisa Wisniewski , who works in a fund that supports innovative biopharmaceutical companies.
Perhaps even more interesting are two lawyers who with this specialization might not have been expected in a noble NGO that claims to be dedicated to protecting wildlife and public health from emerging diseases. This is Geoffrey Potter, who is a partner at Patterson Belknap and heads the brand protection and anti-piracy department; and David McIntyre, who handles such cases at legal services firm Axiom and who was previously at Johnson & Johnson. In connection with pharmaceutical companies and investment banking, the two are of course very suitable. [Digression: The real scandal about the Astra Zeneca vaccine is that it is being marketed for no profit. Accordingly, and because of the technology that has been in existence for a long time, it is also much cheaper than the new types of vaccine, which seriously disrupts the

business of other pharmaceutical companies. As much investment as with the other companies is not necessary. Things get even more uncomfortable with a quick vaccination campaign, because the companies with the expensive new technologies have less production capacity and therefore a smaller market share the faster it goes. : End digression].
Then there is a sizeable group of management consultants, recruiters and executive coaches on the board of directors, of which Margaret Loeb , a senior consultant at McKinsey, is arguably the most prominent. She also occasionally provides space at McKinsey for board meetings of the EcoHealth Alliance. We also have a very simple lobbyist. Ben Plumley, is the founder and now Global Health Strategist for Hunuvat. This "social enterprise" (15% of the profits are donated) connects communities, non-governmental organizations and the private sector (someone has to pay) with national and international politicians.
There are still some scientists, even on the board of directors. The initiated can see what it is primarily about from the logo. They are genetic engineering.
Where does the money come from?
The EcoHealth Alliance has annual sales of approximately US $ 17 million and assets of approximately US $ 6.6 million . Somebody has to donate heavily and possibly hope for something from it. However, the EcoHealth Alliance also receives substantial government support for a non-governmental organization. Since 2008, US $ 19.3 million in government funds have flowed . The lion's share of this comes as shown in Figure 1indicated from the Department of Defense, namely US $ 17.19 million. They come from the Weapons of Mass Destruction Program and the project is titled “Understanding the Risk of Bat-borne Zoonotic Diseases in Western Asia”. It is ironic that the US Department of Defense is paying millions to Peter Daszak, who works with a Chinese level 4 institute that has been reportedly run by a major general of the Chinese People's Liberation Army since January 31, 2020 . The state medium Pengbei has Chen Weidescribed as the nation's foremost expert on biological and chemical defense. She led the team that developed the first Chinese vaccine against Covid-19.
Another major funder of the EcoHealth Alliance's scientific research through April 24, 2020 was the National Institutes of Health (NIH). Then they found that the current results were inconsistent with the objectives of the program and the priorities of the NIH and stopped funding. On May 21, 2020, the science magazine Science reportedthat 77 Nobel Prize winners wrote a letter to the NIH director and the US Secretary of Health demanding that this decision be withdrawn. My question would be whether they were informed about what Peter Daszak had applied for as a project at the NIH and what he then did. I don't know any of the 77 so well that I could just call and ask. I asked the two of them, with whom I had previously been in contact on other matters, by email on Friday. I haven't received any answers yet. If they still arrive, I'll submit them under the blog post. It is not likely, however. The NIH decision was then actually reversed, but only subject to conditions that the cooperation partners at the WIV cannot or are not allowed to meet.
Networks in a triangle
We only know the following in detail because there is a Freedom of Information Act in the USA. As a non-governmental organization, the EcoHealth Alliance is not subject to this, but its director Rita Colwell is, because she used an e-mail account at the state-funded University of Maryland. Your e-mails about the processes with the EcoHealth Alliance therefore had to be released .
The fact that Covid-19 broke out in the city where the WIV is researching similar viruses did not escape the public's eye, of course. The question arose as to whether the virus could have escaped from the WIV. After all, research on the predecessor SARS-Cov at an institute in Beijing led to some infections, with the mother of one of the originally infected doctoral students dying. As is always the case in